STOCKHOLM, July 5, 2019 /PRNewswire/ -- Cyxone (publ), a Swedish biotech in autoimmune diseases, today submitted an application to the Central Ethics Committee (CEC) in Poland for permission to start a clinical phase IIb trial with its drug candidate Rabeximod, which is in development for ...
from PR Newswire: https://ift.tt/30ddE6h
No comments:
Post a Comment